Search research articles
Contact Us
Filters
Showing results (151-160 of 173) with videos related to
Page
of 18
Sort By:
American Journal of Physiology. Heart and Circulatory Physiology
|
May 27, 2014
Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury
Lara Gotha, Sang Yup Lim, Azriel B Osherov, et al.
Journal of the American Society of Nephrology : JASN
|
February 13, 2009
Expression, localization, and function of the thioredoxin system in diabetic nephropathy
Andrew Advani, Richard E Gilbert, Kerri Thai, et al.
Cardiovascular Research
|
May 26, 2018
Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation
Antoinette Bugyei-Twum, Christopher Ford, Robert Civitarese, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|
March 5, 2020
Renal tissue Po<sub>2</sub> sensing during acute hemodilution is dependent on the diluent
Jessica R Abrahamson, Austin Read, Kyle Chin, et al.
JACC. Cardiovascular Imaging
|
January 17, 2021
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
Tamique Mason, Otavio R Coelho-Filho, Subodh Verma, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
March 23, 2020
Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial
Karan Bami, Sumeet Gandhi, Howard Leong-Poi, et al.
Circulation
|
November 12, 2019
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C David Mazer, Gregory M T Hare, Philip W Connelly, et al.
Circulation
|
August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma, C David Mazer, Andrew T Yan, et al.
Journal of the American Society of Nephrology : JASN
|
August 27, 2005
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
Marc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, et al.
The Journal of Clinical Investigation
|
January 11, 2012
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice
Tania N Petruzziello-Pellegrini, Darren A Yuen, Andrea V Page, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 173) with videos related to
Sort By:
Page
of 18
American Journal of Physiology. Heart and Circulatory Physiology
|
May 27, 2014
Heparan sulfate side chains have a critical role in the inhibitory effects of perlecan on vascular smooth muscle cell response to arterial injury
Lara Gotha, Sang Yup Lim, Azriel B Osherov, et al.
Journal of the American Society of Nephrology : JASN
|
February 13, 2009
Expression, localization, and function of the thioredoxin system in diabetic nephropathy
Andrew Advani, Richard E Gilbert, Kerri Thai, et al.
Cardiovascular Research
|
May 26, 2018
Sirtuin 1 activation attenuates cardiac fibrosis in a rodent pressure overload model by modifying Smad2/3 transactivation
Antoinette Bugyei-Twum, Christopher Ford, Robert Civitarese, et al.
American Journal of Physiology. Regulatory, Integrative and Comparative Physiology
|
March 5, 2020
Renal tissue Po<sub>2</sub> sensing during acute hemodilution is dependent on the diluent
Jessica R Abrahamson, Austin Read, Kyle Chin, et al.
JACC. Cardiovascular Imaging
|
January 17, 2021
Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease
Tamique Mason, Otavio R Coelho-Filho, Subodh Verma, et al.
Journal of the American Society of Echocardiography : Official Publication of the American Society of Echocardiography
|
March 23, 2020
Effects of Empagliflozin on Left Ventricular Remodeling in Patients with Type 2 Diabetes and Coronary Artery Disease: Echocardiographic Substudy of the EMPA-HEART CardioLink-6 Randomized Clinical Trial
Karan Bami, Sumeet Gandhi, Howard Leong-Poi, et al.
Circulation
|
November 12, 2019
Effect of Empagliflozin on Erythropoietin Levels, Iron Stores, and Red Blood Cell Morphology in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease
C David Mazer, Gregory M T Hare, Philip W Connelly, et al.
Circulation
|
August 23, 2019
Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial
Subodh Verma, C David Mazer, Andrew T Yan, et al.
Journal of the American Society of Nephrology : JASN
|
August 27, 2005
Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations
Marc A Pohl, Samuel Blumenthal, Daniel J Cordonnier, et al.
The Journal of Clinical Investigation
|
January 11, 2012
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice
Tania N Petruzziello-Pellegrini, Darren A Yuen, Andrea V Page, et al.
Page
of 18